BAYR.Y dropped 7.7% on April 24 after reporting first-quarter results — a print that combined with macro unease to push the ADR down 8.5% on the week to $10.60, compressing an already beaten-down name that is off nearly 3% over the past month.
The most striking development in the data is the collapse in short positioning after the Q1 release. Short interest fell 43% in a single session on April 28, and over the rolling week the shorts-on-loan figure has declined 76%. The reset appears to be covering rather than a fresh conviction shift — shares short spiked sharply in the days leading into results, reaching a 30-day peak around April 20-21, before unwinding almost entirely once the print hit. What is left is a residual short count that is thin relative to the past month's range. With the borrow market wide open — availability is essentially unconstrained at current levels — there is no mechanical pressure driving this coverage. Shorts simply got out after a bad week for the stock.
The lending market tells a similar story of orderly rather than forced repositioning. Cost to borrow has drifted lower over the past six weeks, from above 7.9% in early March to around 6.2% now. That gentle decline is consistent with reduced short demand. The ORTEX short score of 28.5 is modest — it briefly spiked to 39 on April 20-21 as shorts built into earnings, then snapped back to its prior range once covering began. Nothing in the borrow data suggests any squeeze dynamic; this is shorts exiting a tactical trade.
Bayer's fundamental picture is complex but not cheap by debt metrics. The enterprise value is roughly $45 billion, with an EV/EBITDA multiple close to 4x on ORTEX data — a low absolute multiple, but one that reflects a heavy net debt load of approximately $37.7 billion. The P/E ratio of around 9x and P/B of 1.2x both trended lower over the past seven days, compressing further on the earnings selloff. The EV/EBIT at 13.8x is the more honest gauge given the company's capital structure, and it has been drifting down steadily. Analyst coverage is limited on the OTC listing and the available consensus data is too dated to carry any weight here; investors in BAYR.Y should reference the primary Frankfurt listing for meaningful Street input.
Institutional ownership is broadly diversified across index and active managers. BlackRock holds the largest OTC-registry position at 7.8% of shares, adding 5.5 million shares in Q1. Capital Research built a notable position as well, adding 4.3 million shares in the most recently reported quarter. These are passive and long-duration flows rather than signals of near-term conviction shifts, but they anchor the register with stickier holders than a speculative short-heavy name would attract.
The next earnings event is flagged for May 12 — just two weeks away. The April 24 Q1 report produced a one-day move of -7.7%, the sharpest reaction in the available history. The prior print in early March moved less than 1% on the day. That asymmetry, and the fact that tactical shorts have already cleared out, means the May 12 setup enters with a cleaner positioning picture than the one that preceded April 24 — and whether the stock finds a floor near current levels or continues to drift will depend on what management says about litigation progress and cash generation.
See the live data behind this article on ORTEX.
Open BAYR.Y on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
